Arcus Biosciences, Inc.

The decrease during the period is primarily due to the use of cash in our research and development activities partially offset by the net proceeds from our underwritten offering in February 2025 and the additional $50 million draw down under our term loan facility in June 2025.

SEC original ↗Arcus Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

(NYSE RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a pipeline update on its clinical-stage investigational molecules across multiple common cancers.

SEC original ↗Arcus Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Etrumadenant (adenosine A2a A2b receptor antagonist) In March 2025, we engaged with the FDA regarding promising results from the ARC-9 study evaluating etrumadenant in third-line metastatic colorectal cancer (mCRC) although the FDA s feedback confirmed the potential for a registrational path for this program in third-line mCRC, based on our strategic priorities, Arcus and Gilead agreed to not pursue a Phase 3 study at this time and, in June 2025, Gilead returned its license to etrumadenant to Arcus.

SEC original ↗Arcus Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

About the Gilead Collaboration In May 2020, Arcus established a 10-year collaboration with Gilead to strategically advance our portfolio.

SEC original ↗Arcus Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Investor Inquiries Pia Eaves VP of Investor Relations Strategy (617) 459-2006 peaves arcusbio.

SEC original ↗Arcus Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Failure to successfully develop, validate and obtain regulatory clearance or approval for such tests could harm our product development strategy or prevent us from realizing the full commercial potential of our investigational products.

SEC original ↗Arcus Biosciences, Inc. — 10-Q Quarterly report10-QAug 5, 2026

All forward-looking statements involve known and unknown risks and uncertainties and other important factors that may cause Arcus s actual results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements.

SEC original ↗Arcus Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Risks and uncertainties facing Arcus are described more fully in the Risk Factors section of Arcus s most recent periodic report filed with the U.

SEC original ↗Arcus Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Legal Proceedings 29 Item 1A.

SEC original ↗Arcus Biosciences, Inc. — 10-Q Quarterly report10-QAug 5, 2026

Exhibits 63 SIGNATURES 64 Table of Contents RISK FACTOR SUMMARY The following is a summary of the key risks and uncertainties that make an investment in our securities speculative and risky.

SEC original ↗Arcus Biosciences, Inc. — 10-Q Quarterly report10-QAug 5, 2026

If we breach our obligations under these agreements, we may be required to pay damages, lose our rights to these investigational products or both, which would adversely affect our business and prospects.

SEC original ↗Arcus Biosciences, Inc. — 10-Q Quarterly report10-QAug 5, 2026

We may become involved in lawsuits alleging that we have infringed the intellectual property rights of third parties or to protect or enforce our patents or other intellectual property, which litigation could be expensive, time consuming and adversely affect our ability to develop or commercialize our investigational products.

SEC original ↗Arcus Biosciences, Inc. — 10-Q Quarterly report10-QAug 5, 2026